EIT-URBAN-MOBILITY
16.11.2021 09:02:12 CET | Business Wire | Press release
Tomorrow.Mobility World Congress (TMWC) is a new global event, co-organised by Fira de Barcelona and EIT Urban Mobility, focused on promoting the design and adoption of new sustainable urban mobility models. TMWC is being launched to create a global benchmark in the field of mobility and to go beyond a one-off event, as it will include an online knowledge platform that will be active throughout the year and an innovation hub set to bring the main players in the industry together.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211116005046/en/
EIT Urban Mobility is the largest European initiative for the transformation of urban mobility, created by the European Institute of Innovation and Technology (EIT), a body of the European Union. This European initiative benefits of the strategic partnership with Fira de Barcelona by increasing the impact of its European partnership and jointly reaching to a wider audience globally in the mobility scene. Tomorrow.Mobility represents EIT Urban Mobility’s flagship event 2021, showcasing its most promising innovation projects, results, demonstrations, and supported start-ups.
TMWC will bring insights from the global mobility ecosystem gathered under one roof. Being aware of the strong ties that mobility has with other sectors, the event is co-located with Smart City Expo World Congress (SCEWC). More than 350 speakers will be joining alongside hundreds of exhibitors and thousands of attendees. Twelve inspiring congress sessions featuring high-level speakers from both the public and private sector will take place under the umbrella of Tomorrow.Mobility. Speakers include Maria Tsavachidis, CEO of EIT Urban Mobility & President of the Board of Tomorrow.Mobility; Matthew Baldwin, Deputy Director-General for DG MOVE, European Commission; Mark Major, Senior Advisor to the Partnership on Sustainable, Low Carbon Transport (SLoCaT); Carlos Moreno, Scientific director of the Chair Entrepreneurship Territory Innovation, University Panthéon Sorbonne – IAE Paris; and Anna Lisa Boni, Secretary General at Eurocities.
Dr. Maria Tsavachidis, CEO of EIT Urban Mobility & President of the Advisory Board of TMWC stated that “our collaboration with Fira de Barcelona will help expand the network of innovation for urban mobility in Europe and beyond. Our goal is to foster innovation and transformation towards sustainable mobility, to decarbonise mobility, improve people’s quality of life, and make Europe’s economy more competitive. Bringing together the world´s leaders and frontrunners in sustainable mobility under the umbrella of Tomorrow.Mobility is an important steppingstone towards this goal. It will inspire and create new opportunities for our partners, cities, startups, and their innovations ”.
Numerous start-ups supported by EIT Urban Mobility will be showcasing their high-tech solutions at their booths and demo areas, such as: Bia Power (Autonomous Vehicles/Spain), BlockCity (Mobility Services/Hungary), Dashfactory Gmbh (Sensors & Training Data/Germany), Delivers.ai (Last Mile Delivery/Turkey), Vianova (Sensors Data/France), and SmartMonkey (Green Logistics/Spain).
Several EIT Urban Mobility supported innovation projects will be featured at the Central Agora during two different sessions. One session focusing on managing shared public space, and another on how to put Mobility as a Service (MaaS) solutions into practice. Among the EIT Urban Mobility supported projects presented are, FURNISH , which promotes the redesign of public spaces to prevent the spread of COVID-19. Another notable project is HALLO, which creates shared urban consolidation and distribution centres through a series of pilots in Barcelona and Stockholm.
Tomorrow.Mobility, held with the Smart City Expo World Congress (SCEWC), a leading tradeshow & congress on smart cities, has the initial support of over a hundred global companies and trusted institutions amongst which feature the World Bank, the World Economic Forum, the United Nations, Microsoft, Mastercard, ADP (Airports of Paris), the International Association of Ports and Harbours, the Port of Barcelona, Moventia, the RACC and Social Car. The event seeks to tackle the future challenges facing mobility, an industry that will be one of the main drivers of future growth, with a market volume of 60,000 million euros in 2027.
The new event, which will include a congress and exhibition area, will hold a first pilot edition in November and again in 2022. It will address current mobility challenge areas such as micromobility (electric scooters, bicycles), active mobility and the public realm, public transport, mobility providers (car sharing, air taxis), the car industry (electric, connected, and autonomous cars), last mile logistics (e-commerce deliveries, delivery drones), smart infrastructures (fleet management, geolocation, and payment systems), the energy transition towards carbon neutrality and digitisation.
The objective of Tomorrow.Mobility is to go beyond being just an event. The launch of the new show will be accompanied by the creation of a digital content platform with a global reach operating 365 days a year, turning it into the go-to global stage for urban, sustainable, and smart mobility. This platform will allow access to both live events and à la carte contents divided into themes with the aim of facilitating knowledge transfer, training & network.
Practical information
- Dates: 16, 17 & 18 November 2021
- Opening hours: Tue & Wed: 9.00-19.00 CET | Thu: 9.00-17.00 CET
-
Location:
Fira de Barcelona Gran Via – Halls 1 & 2 -
Av. Joan Carles I, 64 - 08908 L’Hospitalet de Llobregat, Barcelona, Spain - EIT Urban Mobility Booth @ Tomorrow.Mobility: Street D, Stand 174
- Event website: www.tomorrowmobility.com
BACKGROUND
About EIT Urban Mobility
EIT Urban Mobility, an initiative of the European Institute of Innovation and Technology (EIT)
, a body of the European Union, aims to accelerate solutions and the transition towards a user-centric, integrated and truly multimodal transport system. As the leading European innovation community for urban mobility, EIT Urban Mobility works to avoid fragmentation by facilitating collaboration between cities, industry, academia, research and innovation to solve the most pressing mobility challenges of cities. Using cities as living labs, its industry, research and university partners will demonstrate how new technologies can work to solve real problems in real cities by transporting people, goods and waste in smarter ways.
For more information visit www.eiturbanmobility.eu .
Follow EIT Urban Mobility on: Linkedin Twitter Facebook Youtube Instagram
View source version on businesswire.com: https://www.businesswire.com/news/home/20211116005046/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom